Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis
Tetsuya Ikawa
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorTakuya Miyagawa
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuki Fukui
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorSatoshi Toyama
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorJun Omatsu
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorKentaro Awaji
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuta Norimatsu
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYusuke Watanabe
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorAyumi Yoshizaki
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorShinichi Sato
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Yoshihide Asano
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Correspondence
Yoshihide Asano, Department of Dermatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Email: [email protected]
Search for more papers by this authorTetsuya Ikawa
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorTakuya Miyagawa
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuki Fukui
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorSatoshi Toyama
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorJun Omatsu
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorKentaro Awaji
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuta Norimatsu
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYusuke Watanabe
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorAyumi Yoshizaki
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorShinichi Sato
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Yoshihide Asano
Department of Dermatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Correspondence
Yoshihide Asano, Department of Dermatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Email: [email protected]
Search for more papers by this authorThis work was supported by a grant for Research in Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan. The funder is not involved in study design, data collection, data analysis, manuscript preparation, and publication decisions.
Abstract
Aim
Systemic sclerosis (SSc) is an autoimmune connective tissue disease, in which extensive fibrotic change and vasculopathy affect the skin and various internal organs. It also involves the joints, causing stiffness, arthralgia, and arthritis. Although arthropathy is commonly observed in SSc, its underlying mechanism remains unknown. CXCL12, also known as stromal cell derived factor 1, is associated with inflammation, mesenchymal cell recruitment, angiogenesis, and collagen production, and is implicated in the development of various joint diseases. To assess the potential contribution of CXCL12 to SSc development, we investigated the clinical association of serum CXCL12 levels in patients with SSc.
Method
We conducted a cross-sectional analysis of 68 patients with SSc and 20 healthy controls recruited in a single center over 9 years. Serum CXCL12 levels were measured by enzyme-linked immunosorbent assay.
Results
Serum CXCL12 levels were significantly higher in patients with SSc than in healthy controls (median 1554.0 pg/mL, 25th-75th centiles 1313.0-1914.0 pg/mL vs 967.4 pg/mL, 608.8-1271.0 pg/mL, P < 0.001). Patients with SSc with elevated CXCL12 levels had significantly more cases of arthropathy than those with normal CXCL12 levels (85.7% vs 25.0%, P = 0.01). Furthermore, patients with SSc with elevated CXCL12 levels showed an increased trend in the prevalence of limited range of motion of the finger joints compared with those with normal CXCL12 levels (60.0% vs 18.6%, P =0 .07). Moreover, serum CXCL12 levels were significantly correlated with the titers of rheumatoid factor in patients with SSc (r = .41, P = 0.001).
Conclusion
Elevated serum CXCL12 levels may be related to the development of SSc arthropathy.
Conflict of interest
The authors have no conflicts of interest to declare.
REFERENCES
- 1Asano Y. Systemic sclerosis. J Dermatol. 2018; 45: 128–138.
- 2Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390: 1685–1699.
- 3Schmeiser T, Pons-Kuhnemann J, Ozden F, Muller-Ladner U, Dinser R. Arthritis in patients with systemic sclerosis. Eur J Intern Med. 2012; 23: e25–29.
- 4King J, Abraham D, Stratton R. Chemokines in systemic sclerosis. Immunol Lett. 2018; 195: 68–75.
- 5Stone MJ, Hayward JA, Huang C, E. Huma Z, Sanchez J. Mechanisms of Regulation of the Chemokine-Receptor Network. Int J Mol Sci. 2017; 18: 342–374.
- 6Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005; 52: 2889–2896.
- 7van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M, York M, Collins C, Wenink M, Huijbens R, Hesselstrand R, Saxne T, DiMarzio M, Wuttge D, Agarwal SK, Reveille JD, Assassi S, Mayes M, Deng Y, Drenth JPH, de Graaf J, den Heijer M, Kallenberg CGM, Bijl M, Loof A, van den Berg WB, Joosten LAB, Smith V, de Keyser F, Scorza R, Lunardi C, van Riel PLCM, Vonk M, van Heerde W, Meller S, Homey B, Beretta L, Roest M, Trojanowska M, Lafyatis R, Radstake TRDJ. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014; 370: 433–443.
- 8Janssens R, Struyf S, Proost P. Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev. 2018; 44: 51–68.
- 9Villalvilla A, Gomez R, Roman-Blas JA, Largo R, Herrero-Beaumont G. SDF-1 signaling: a promising target in rheumatic diseases. Expert Opin Ther Targets. 2014; 18: 1077–1087.
- 10Kitaori T, Ito H, Schwarz EM, Tsutsumi R, Yoshitomi H, Oishi S, Nakano M, Fujii N, Nagasawa T, Nakamura T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009; 60: 813–823.
- 11Bragg R, Gilbert W, Elmansi AM, Isales CM, Hamrick MW, Hill WD, Fulzele S. Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis. Ther Adv Chronic Dis. 2019; 10: 2040622319882531.
- 12Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382: 635–638.
- 13Macoska JA, Wang Z, Virta J, Zacharias N, Bjorling DE. Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo. Prostate. 2019; 79: 757–767.
- 14Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002; 46: 2587–2597.
- 15Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858–864.
- 16Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015; 37: 489–500.
- 17LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15: 202–205.
- 18van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE, Pope J. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737–2747.
- 19Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman AJ, Allegar N, Varga J, Massa M. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993; 20: 1892–1896.
- 20Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015; 46: 903–975.
- 21McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001; 104: 2797–2802.
- 22Miyagawa T, Taniguchi T, Saigusa R, Fukayama M, Takahashi T, Yamashita T, Hirabayashi M, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2020; 59: 2005–2015.
- 23Beaudoin J, Szymonifka J, Lavender Z, Deaño RC, Zhou Q, Januzzi JL, Singh JP, Truong QA. Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy. J Thorac Dis. 2019; 11: 5362–5371.
- 24Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012; 51: 1347–1356.
- 25Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, Eustar Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schoffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010; 37: 1488–1501.
- 26Palmer DG, Hale GM, Grennan DM, Pollock M. Bowed fingers. A helpful sign in the early diagnosis of systemic sclerosis. J Rheumatol. 1981; 8: 266–272.
- 27Akbayrak E, Dinser R, Muller-Ladner U, Tarner IH. Low-field magnetic resonance imaging study on carpal arthritis in systemic sclerosis–low-grade erosive arthritis of carpal bones is an unexpected and frequent disease manifestation. Arthritis Res Ther. 2013; 15: R2.
- 28Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res. 2003; 18: 1404–1418.
- 29Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000; 165: 6590–6598.
- 30Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, Garcia-Lazaro FJ. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003; 170: 2147–2152.
- 31Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Segal MS, Grant MB, Scott EW. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005; 115: 86–93.
- 32Hansen IB, Ellingsen T, Hornung N, Poulsen JH, Lottenburger T, Stengaard-Pedersen K. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment. J Rheumatol. 2006; 33: 1754–1759.
- 33Dziankowska-Bartkowiak B, Gerlicz-Kowalczuk Z, Waszczykowska E. Angiogenin and SDF-1alpha serum concentration in patients with systemic sclerosis in relation to clinical status. Arch Med Sci. 2011; 7: 92–96.
- 34Kanbe K, Takagishi K, Chen Q. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum. 2002; 46: 130–137.
10.1002/1529-0131(200201)46:1<130::AID-ART10020>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 35Xu Q, Sun XC, Shang XP, Jiang HS. Association of CXCL12 levels in synovial fluid with the radiographic severity of knee osteoarthritis. J Investig Med. 2012; 60: 898–901.
- 36Kim HR, Kim KW, Kim BM, Jung HG, Cho ML, Lee SH. Reciprocal activation of CD4+ T cells and synovial fibroblasts by stromal cell-derived factor 1 promotes RANKL expression and osteoclastogenesis in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66: 538–548.
- 37Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol. 2004; 199: 244–251.
- 38Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum. 2007; 56: 1854–1868.
- 39Wei F, Moore DC, Wei L, Li Y, Zhang G, Wei X, Lee JK, Chen Q. Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway. Arthritis Res Ther. 2012; 14: R177.
- 40Kanbe K, Takemura T, Takeuchi K, Chen Q, Takagishi K, Inoue K. Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br. 2004; 86: 296–300.
- 41Mazzetti I, Magagnoli G, Paoletti S, Uguccioni M, Olivotto E, Vitellozzi R, Cattini L, Facchini A, Borzi RM. A role for chemokines in the induction of chondrocyte phenotype modulation. Arthritis Rheum. 2004; 50: 112–122.
- 42Li P, Deng J, Wei X, Jayasuriya CT, Zhou J, Chen Q, Zhang J, Wei L, Wei F. Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13. Mol Med Rep. 2016; 14: 1475–1482.
- 43Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum. 1998; 41: 2211–2220.
- 44Wielosz E, Majdan M, Dryglewska M, Zwolak R. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations. Adv Clin Exp Med. 2018; 27: 1253–1257.
- 45Manetti M, Liakouli V, Fatini C, Cipriani P, Bonino C, Vettori S, Guiducci S, Montecucco C, Abbate R, Valentini G, Matucci-Cerinic M, Giacomelli R, Ibba-Manneschi L. Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. Ann Rheum Dis. 2009; 68: 408–411.
- 46Kimura R, Nishioka T, Soemantri A, Ishida T. Allele-specific transcript quantification detects haplotypic variation in the levels of the SDF-1 transcripts. Hum Mol Genet. 2005; 14: 1579–1585.
- 47Cipriani P, Franca Milia A, Liakouli V, Pacini A, Manetti M, Marrelli A, Toscano A, Pingiotti E, Fulminis A, Guiducci S, Perricone R, Kahaleh B, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis Rheum. 2006; 54: 3022–3033.
Citing Literature
